SYNNF yields 434.78% · JNJ yields 2.13%● Live data
📍 SYNNF pulled ahead of the other in Year 1
Combined, SYNNF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SYNNF + JNJ for your $10,000?
Symphony International Holdings Limited is a private equity and venture capital firm specializing in investments in early stage, management buy-outs, emerging growth, management buy-ins, restructurings, special situations, and the provision of growth capital for later-stage development and expansion. It also invests in real estate development. The firm typically invests in innovative and high-growth consumer businesses, new economy, primarily in the education, hospitality, lifestyle logistics, new economy, healthcare, healthcare related services, luxury branded real estate, hospitality and lifestyle sectors. It prefers to make long-term direct investments in the Asia Pacific region with a focus on Australia, India, Indonesia, Malaysia, Singapore, Taiwan, Thailand, Vietnam and Sri Lanka. The firm seeks to achieve control and majority positions in partnership with the management of the acquired business. It seeks to be the lead or sole investor. Symphony International Holdings Limited was founded in 2004 and is based in British Virgin Islands.
Full SYNNF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.